Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Methodological aspects of health-related quality of life measurement and analysis in patients with multiple myeloma

    Research output: Contribution to journalReviewResearchpeer-review

  2. Outcome of an enhanced diagnostic pipeline for patients suspected of inherited thrombocytopenia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Genetic predisposition to PEG-asparaginase hypersensitivity in children treated according to NOPHO ALL2008

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Clonal hematopoiesis in elderly twins: concordance, discordance and mortality

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Mantle cell lymphoma (MCL) is an aggressive B cell lymphoma, where survival has been remarkably improved by use of protocols including high dose cytarabine, rituximab and autologous stem cell transplantation, such as the Nordic MCL2/3 protocols. In 2008, a MCL international prognostic index (MIPI) was created to enable stratification of the clinical diverse MCL patients into three risk groups. So far, use of the MIPI in clinical routine has been limited, as it has been shown that it inadequately separates low and intermediate risk group patients. To improve outcome and minimize treatment-related morbidity, additional parameters need to be evaluated to enable risk-adapted treatment selection. We have investigated the individual prognostic role of the MIPI and molecular markers including SOX11, TP53 (p53), MKI67 (Ki-67) and CCND1 (cyclin D1). Furthermore, we explored the possibility of creating an improved prognostic tool by combining the MIPI with information on molecular markers. SOX11 was shown to significantly add prognostic information to the MIPI, but in multivariate analysis TP53 was the only significant independent molecular marker. Based on these findings, we propose that TP53 and SOX11 should routinely be assessed and that a combined TP53/MIPI score may be used to guide treatment decisions.

Original languageEnglish
JournalBritish Journal of Haematology
Volume166
Issue number1
Pages (from-to)98-108
Number of pages11
ISSN0007-1048
DOIs
Publication statusPublished - Jul 2014

    Research areas

  • Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Child, Cohort Studies, Cyclin D1, Female, Humans, Lymphoma, Mantle-Cell, Male, Neoplasm Proteins, Neoplasm Staging, Prognosis, SOXC Transcription Factors, Severity of Illness Index, Survival Analysis, Treatment Outcome, Tumor Markers, Biological, Tumor Suppressor Protein p53

ID: 44704987